🇺🇸 Aricept (donepezil IR 10 mg) in United States

FDA authorised Aricept (donepezil IR 10 mg) on 18 October 2004

Marketing authorisations

FDA — authorised 18 October 2004

  • Application: NDA021720
  • Marketing authorisation holder: EISAI INC
  • Local brand name: ARICEPT ODT
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 11 December 2009

  • Application: ANDA077975
  • Marketing authorisation holder: SUN PHARM INDUSTRIES
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 29 June 2010

  • Application: ANDA077344
  • Marketing authorisation holder: HERITAGE PHARMA
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 26 November 2010

  • Application: ANDA076786
  • Marketing authorisation holder: SUN PHARM INDS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 26 November 2010

  • Application: ANDA078388
  • Marketing authorisation holder: CHARTWELL RX
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 10 May 2011

  • Application: ANDA090175
  • Marketing authorisation holder: ZYDUS PHARMS USA INC
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 10 May 2011

  • Application: ANDA091198
  • Marketing authorisation holder: AIPING PHARM INC
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090551
  • Marketing authorisation holder: NOVITIUM PHARMA
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA077518
  • Marketing authorisation holder: CIPLA LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA200292
  • Marketing authorisation holder: PRINSTON INC
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090425
  • Marketing authorisation holder: CHARTWELL RX
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090768
  • Marketing authorisation holder: JUBILANT GENERICS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090290
  • Marketing authorisation holder: AIPING PHARM INC
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA091267
  • Marketing authorisation holder: WOCKHARDT
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA078662
  • Marketing authorisation holder: STRIDES PHARMA
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA201001
  • Marketing authorisation holder: DR REDDYS LABS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090521
  • Marketing authorisation holder: NATCO PHARMA
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090686
  • Marketing authorisation holder: TORRENT PHARMS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090247
  • Marketing authorisation holder: HIKMA PHARMS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 May 2011

  • Application: ANDA090493
  • Marketing authorisation holder: SUN PHARM INDS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 2 June 2011

  • Application: ANDA078841
  • Marketing authorisation holder: APOTEX
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 13 June 2011

  • Application: ANDA201634
  • Marketing authorisation holder: INDICUS PHARMA
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 29 August 2011

  • Application: ANDA201335
  • Marketing authorisation holder: ACCORD HLTHCARE
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 17 August 2012

  • Application: ANDA201146
  • Marketing authorisation holder: MACLEODS PHARMS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 24 October 2012

  • Application: ANDA090100
  • Marketing authorisation holder: ZYDUS LIFESCIENCES
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 14 December 2012

  • Application: ANDA201787
  • Marketing authorisation holder: MACLEODS PHARMS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 25 February 2013

  • Application: ANDA201724
  • Marketing authorisation holder: ALEMBIC PHARMS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 5 July 2013

  • Application: ANDA202114
  • Marketing authorisation holder: RISING
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 24 July 2013

  • Application: ANDA202723
  • Marketing authorisation holder: DR REDDYS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 24 July 2013

  • Application: ANDA202542
  • Marketing authorisation holder: PH HEALTH
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 22 January 2014

  • Application: ANDA202631
  • Marketing authorisation holder: MACLEODS PHARMS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 23 December 2014

  • Application: NDA206439
  • Marketing authorisation holder: ABBVIE
  • Local brand name: NAMZARIC
  • Indication: CAPSULE, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA — authorised 30 January 2015

  • Application: ANDA203034
  • Marketing authorisation holder: HETERO LABS LTD V
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 22 October 2015

  • Application: ANDA202656
  • Marketing authorisation holder: RISING
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 19 February 2016

  • Application: ANDA203713
  • Marketing authorisation holder: DEXCEL
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 12 April 2016

  • Application: ANDA203419
  • Marketing authorisation holder: CHARTWELL RX
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 23 June 2016

  • Application: ANDA203656
  • Marketing authorisation holder: UNICHEM
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 10 November 2016

  • Application: ANDA204831
  • Marketing authorisation holder: UNICHEM
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 27 January 2017

  • Application: ANDA208328
  • Marketing authorisation holder: AMNEAL
  • Local brand name: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
  • Indication: CAPSULE, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA — authorised 31 August 2017

  • Application: ANDA203162
  • Marketing authorisation holder: ZYDUS PHARMS
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 19 September 2017

  • Application: ANDA204609
  • Marketing authorisation holder: CADILA PHARMS LTD
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA — authorised 27 July 2018

  • Application: ANDA205269
  • Marketing authorisation holder: HISUN PHARM HANGZHOU
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET, ORALLY DISINTEGRATING — ORAL
  • Status: approved

Read official source →

FDA — authorised 15 December 2023

  • Application: ANDA208237
  • Marketing authorisation holder: ANI PHARMS
  • Local brand name: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
  • Indication: CAPSULE, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA — authorised 15 July 2025

  • Application: ANDA208672
  • Marketing authorisation holder: MACLEODS PHARMS LTD
  • Local brand name: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
  • Indication: CAPSULE, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA — authorised 15 July 2025

  • Application: ANDA216901
  • Marketing authorisation holder: XIAMEN LP PHARM CO
  • Local brand name: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
  • Indication: CAPSULE, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA

  • Application: ANDA076893
  • Marketing authorisation holder: PAR PHARM
  • Local brand name: DONEPEZIL HYDROCHLORIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

Other Neurology approved in United States

Frequently asked questions

Is Aricept (donepezil IR 10 mg) approved in United States?

Yes. FDA authorised it on 18 October 2004; FDA authorised it on 11 December 2009; FDA authorised it on 29 June 2010.

Who is the marketing authorisation holder for Aricept (donepezil IR 10 mg) in United States?

EISAI INC holds the US marketing authorisation.